Table 4

Student's t-test (paired) analyses for comparison of the scores obtained from the low-dose and high-dose 5-Loxin® groups at day 90

n

Baseline

Day 90

95% CI (versus placebo)

P

Mean

SD

Mean

SD


Visual analogue scale score

Placebo

23

56.88

12.04

41.76

15.98

<0.05

100 mg 5-Loxin®

24

57.05

8.71

21.37

7.13

-27.67, -13.11

<0.0001

250 mg 5-Loxin®

23

55.62

9.26

14.22

6.8

-34.94, -20.19

<0.0001

Lequesne's Functional Index

Placebo

23

12.76

2.6

10.19

3.24

0.031

100 mg 5-Loxin®

24

12.1

2.76

7.78

4.61

-4.74, -0.07

<0.0001

250 mg 5-Loxin®

23

12.04

3.03

7

3.5

-5.19, -1.18

<0.0001

WOMAC pain subscale

Placebo

23

38.04

2.03

31.74

2.58

0.1212

100 mg 5-Loxin®

24

42.08

2.93

19.17

3.55

-21.33, to -3.83

<0.0001

250 mg 5-Loxin®

23

37.17

2.88

15.22

2.50

-23.78 to -9.28

<0.0001

WOMAC stiffness subscale

Placebo

23

33.15

2.73

24.45

2.37

0.2983

100 mg 5-Loxin®

24

31.77

3.61

14.06

3.71

-38.87, -6.85

<0.0001

250 mg 5-Loxin®

23

27.72

3.44

9.24

2.07

-43.35, -17.45

<0.0001

WOMAC function subscale

Placebo

23

41.30

2.02

34.07

1.09

0.1048

100 mg 5-Loxin®

24

41.48

2.31

24.32

4.28

-18.64, -0.82

<0.0001

250 mg 5-Loxin®

23

38.56

2.32

17.267

1.98

-21.39, -12.23

<0.0001

MMP-3 (ng/ml)

Placebo

15

902.1

275.6

928.5

216.02

0.4886

100 mg 5-Loxin®

16

893.6

270.1

637.2

224.5

<0.0001

250 mg 5-Loxin®

14

926.9

270.5

497.5

167.5

<0.0001


CI, confidecne interval; MMP, matrix metalloproteinase; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Sengupta et al. Arthritis Research & Therapy 2008 10:R85   doi:10.1186/ar2461

Open Data